Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension

Kenichiro Kinouchi, Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Hiroshi Itoh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension. Thirty consecutive Japanese diabetic patients with hypertension were randomly assigned to group A, receiving losartan alone for the first 3 months, then L/HCTZ for the next 3 months, or group B, receiving L/HCTZ for the first 3 months, then losartan alone for the next 3 months. Clinical and biological parameters were obtained before, and 3 and 6 months after the start of this study. The decreases in systolic and diastolic blood pressure (BP) during treatment with L/HCTZ were significantly greater than in treatment with losartan alone. Both treatments significantly and similarly decreased urinary albumin excretion, the cardio-ankle vascular index (CAVI) and augmentation index (AI). There was no significant difference in metabolic change during both the mono-and combination pharmacotherapies. The tablet combining L/HCTZ significantly reduced systolic and diastolic BP compared with the losartan monotherapy, and offered benefits similar to losartan monotherapy for albuminuria, arterial stiffness assessed by the CAVI and AI, and metabolic effects. Thus, the L/HCTZ tablet could be a useful drug for Japanese diabetic patients with hypertension.

Original languageEnglish
Pages (from-to)1143-1147
Number of pages5
JournalHypertension Research
Volume32
Issue number12
DOIs
Publication statusPublished - 2009 Dec 23

Fingerprint

Losartan
Tablets
Hypertension
Safety
Blood Pressure
Ankle
Blood Vessels
Vascular Stiffness
Albuminuria
losartan drug combination hydrochlorothiazide
Albumins
Therapeutics
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Albuminuria
  • Angiotensin
  • Arterial stiffness
  • Blood pressure
  • Diuretics

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. / Kinouchi, Kenichiro; Ichihara, Atsuhiro; Sakoda, Mariyo; Kurauchi-Mito, Asako; Itoh, Hiroshi.

In: Hypertension Research, Vol. 32, No. 12, 23.12.2009, p. 1143-1147.

Research output: Contribution to journalArticle

Kinouchi, Kenichiro ; Ichihara, Atsuhiro ; Sakoda, Mariyo ; Kurauchi-Mito, Asako ; Itoh, Hiroshi. / Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. In: Hypertension Research. 2009 ; Vol. 32, No. 12. pp. 1143-1147.
@article{ee37c5adb3a24760a59b8a919da16298,
title = "Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension",
abstract = "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension. Thirty consecutive Japanese diabetic patients with hypertension were randomly assigned to group A, receiving losartan alone for the first 3 months, then L/HCTZ for the next 3 months, or group B, receiving L/HCTZ for the first 3 months, then losartan alone for the next 3 months. Clinical and biological parameters were obtained before, and 3 and 6 months after the start of this study. The decreases in systolic and diastolic blood pressure (BP) during treatment with L/HCTZ were significantly greater than in treatment with losartan alone. Both treatments significantly and similarly decreased urinary albumin excretion, the cardio-ankle vascular index (CAVI) and augmentation index (AI). There was no significant difference in metabolic change during both the mono-and combination pharmacotherapies. The tablet combining L/HCTZ significantly reduced systolic and diastolic BP compared with the losartan monotherapy, and offered benefits similar to losartan monotherapy for albuminuria, arterial stiffness assessed by the CAVI and AI, and metabolic effects. Thus, the L/HCTZ tablet could be a useful drug for Japanese diabetic patients with hypertension.",
keywords = "Albuminuria, Angiotensin, Arterial stiffness, Blood pressure, Diuretics",
author = "Kenichiro Kinouchi and Atsuhiro Ichihara and Mariyo Sakoda and Asako Kurauchi-Mito and Hiroshi Itoh",
year = "2009",
month = "12",
day = "23",
doi = "10.1038/hr.2009.162",
language = "English",
volume = "32",
pages = "1143--1147",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension

AU - Kinouchi, Kenichiro

AU - Ichihara, Atsuhiro

AU - Sakoda, Mariyo

AU - Kurauchi-Mito, Asako

AU - Itoh, Hiroshi

PY - 2009/12/23

Y1 - 2009/12/23

N2 - This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension. Thirty consecutive Japanese diabetic patients with hypertension were randomly assigned to group A, receiving losartan alone for the first 3 months, then L/HCTZ for the next 3 months, or group B, receiving L/HCTZ for the first 3 months, then losartan alone for the next 3 months. Clinical and biological parameters were obtained before, and 3 and 6 months after the start of this study. The decreases in systolic and diastolic blood pressure (BP) during treatment with L/HCTZ were significantly greater than in treatment with losartan alone. Both treatments significantly and similarly decreased urinary albumin excretion, the cardio-ankle vascular index (CAVI) and augmentation index (AI). There was no significant difference in metabolic change during both the mono-and combination pharmacotherapies. The tablet combining L/HCTZ significantly reduced systolic and diastolic BP compared with the losartan monotherapy, and offered benefits similar to losartan monotherapy for albuminuria, arterial stiffness assessed by the CAVI and AI, and metabolic effects. Thus, the L/HCTZ tablet could be a useful drug for Japanese diabetic patients with hypertension.

AB - This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension. Thirty consecutive Japanese diabetic patients with hypertension were randomly assigned to group A, receiving losartan alone for the first 3 months, then L/HCTZ for the next 3 months, or group B, receiving L/HCTZ for the first 3 months, then losartan alone for the next 3 months. Clinical and biological parameters were obtained before, and 3 and 6 months after the start of this study. The decreases in systolic and diastolic blood pressure (BP) during treatment with L/HCTZ were significantly greater than in treatment with losartan alone. Both treatments significantly and similarly decreased urinary albumin excretion, the cardio-ankle vascular index (CAVI) and augmentation index (AI). There was no significant difference in metabolic change during both the mono-and combination pharmacotherapies. The tablet combining L/HCTZ significantly reduced systolic and diastolic BP compared with the losartan monotherapy, and offered benefits similar to losartan monotherapy for albuminuria, arterial stiffness assessed by the CAVI and AI, and metabolic effects. Thus, the L/HCTZ tablet could be a useful drug for Japanese diabetic patients with hypertension.

KW - Albuminuria

KW - Angiotensin

KW - Arterial stiffness

KW - Blood pressure

KW - Diuretics

UR - http://www.scopus.com/inward/record.url?scp=73849090805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849090805&partnerID=8YFLogxK

U2 - 10.1038/hr.2009.162

DO - 10.1038/hr.2009.162

M3 - Article

VL - 32

SP - 1143

EP - 1147

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 12

ER -